source
- Gossamer Bio regains rights to lung disease asset from Chiesi after Phase 3 failure, eyes FDA submissionGossamer Bio announced that it has taken back the rights to its inhaled pulmonary hypertension candidate from partner Chiesi after the drug failed to meet its primary endpoint in a Phase 3 trial.…
- MapLight’s schizophrenia drug misses primary endpoint in Phase 2, shares tumble over 60%MapLight Therapeutics reported results from a mid‑stage Phase 2 trial of its experimental schizophrenia therapy. The study evaluated a once‑daily dosing regimen and failed to meet the predefined p…